If you are passionate about health sciences research that makes a difference in people's lives, you're in good hands. We offer award-wining graduate programs led by world-class researchers. You'll have access to top-tier facilities and be working alongside the best and brightest in the field, conducting research that addresses real life problems. Our paradigm-changing approach is collaborative, innovative, and results-driven.
We're tackling diseases like asthma / chronic obstructive pulmonary disease, diabetes, cancer, heart disease, and arthritis. We're developing better ways to deliver drugs and prevent adverse drug reactions. And we're conducting clinical and economic research in pharmaceutical outcomes.
Our reputation as a top research centre attracts some of the brightest and most productive minds in the field. Our faculty includes Canada Research Chairs, Michael Smith Foundation for Health Research Scholars and Senior Scholars, and Distinguished University Scholars.
We are innovators in pharmacy education, research and practice, with the goal of supporting the optimization of drug therapy in the pursuit of improved patient outcomes.
- We support our people, creating a community that enables excellence through collective action.
- We seek novel ideas, putting into practice those with the greatest scope for sustained impact.
- We search for relevant connections, fostering meaningful collaborations that provide mutual benefit.
adMare BioInnovations is located in our building. It is an independent, non-profit organization with a focus on bridging the gap between academic discoveries in the health sciences and the development of new medicines to treat human disease. The Faculty partners with adMare BioInnovations to provide unique research and mentoring opportunities for MSc and PhD students.
We are also home to several sophisticated research centres that specialize in the areas of human genome and exome sequencing, and health outcomes research.
Opened in 2012, the Pharmaceutical Sciences Building at UBC is a state-of-the-art learning and research facility. The building houses modern, modular labs designed specifically for the type of research intended for the space. Our classroom facilities are fitted with advanced technology to facilitate new modes of learning.
Measuring 246,000 square feet, it's an eye-catching addition to our campus, and has drawn attention and admiration from around the world—including 15 awards of excellence.
As a leading research faculty, we conduct ground-breaking research in the pharmaceutical sciences – all with the goal of addressing the pressing health needs of society and improving lives. Our research activities centre around four areas of focus.
Epidemiology & Health Outcomes
This theme covers our activities in epidemiological analysis, health outcomes and health economics research seeking solutions for the predictive enhancement of intervention strategies for practical and preventive healthcare. The impact of this work is used to shape policy to optimize the allocation of health care resources as well as defining the efficacy of healthcare interventions and strategy.
Molecular & Systems Pharmacology
This highly interdisciplinary theme embodies research directed at the interactions of therapeutic agents with human cells, and covers fundamental questions of the mechanisms of the drug action through to the behaviour of drugs in human systems. These studies are used to inform and optimize the development and delivery of drug intervention regimes for clinical practice and the pharmaceutical industry.
Nanomedicine & Chemical Biology
This theme applies our expertise in the chemical biology of the fabrication and handling of nanoscopic materials to drug discovery and delivery. Sensing and screening technologies are also an important focus.
Our research in this theme addresses the issue of scholarship in pharmacy and the pharmaceutical sciences with a view to augment our educational research capacity and enhance the methodologies of teaching practice, student learning and curriculum decision-making.
Graduate Degree Programs
This is an incomplete sample of recent publications in chronological order by UBC faculty members with a primary appointment in the Faculty of Pharmaceutical Sciences.
Recent Thesis Submissions
The neuroprotective role of somatostatin against beta amyloid induced toxicity in in vitro models of Alzheimer’s disease (Pharmaceutical Sciences - PHD)
Characterization of the effects of a high fat-high sucrose diet in wild-type and ROCK2 heterozygous mice (Pharmaceutical Sciences - MSC)
Benzisothiazole based anti-viral agents : new chemistry revealed during structure-activity relationship studies (Pharmaceutical Sciences - PHD)
Understanding the epidemiology of young-onset colorectal cancer and information needs of patients and survivors (Pharmaceutical Sciences - MSC)
Development of efficient strategies for the synthesis of compound libraries of anti-HIV agents that block HIV replication (Pharmaceutical Sciences - PHD)
Safety of perinatal biologic use in autoimmune diseases : population-based studies of maternal and infant outcomes (Pharmaceutical Sciences - PHD)
Antibiotic-loaded polymeric microspheres for passive lung targeting after intravenous administration (Pharmaceutical Sciences - PHD)
Pharmacokinetic/pharmacodynamic modeling can guide drug candidate optimization (Pharmaceutical Sciences - MSC)
Population-level studies of the incremental economic burden of systemic autoimmune rheumatic diseases (Pharmaceutical Sciences - PHD)
Evaluating strategies for the early detection of chronic obstructive pulmonary disease (Pharmaceutical Sciences - PHD)
Regulation and function of heparanase in the heart (Pharmaceutical Sciences - PHD)
Crosstalk between somatostatin receptor subtypes and cannabinoid receptor 1 in excitotoxicity (Pharmaceutical Sciences - PHD)
Octadentate chelators for zirconium- and other metal-based radiopharmaceuticals (Pharmaceutical Sciences - PHD)
Cholesterol metabolism as a target in castration-resistant prostate cancer (Pharmaceutical Sciences - PHD)
Assessment of atrial fibrillation patients' education needs. (Pharmaceutical Sciences - MSC)
|2016||Dr. Knuhtsen worked on an interdisciplinary project within the fields of peptide chemistry and epigenetics. Based on a lead a library of peptides were synthesized which was used to identify an inhibitor of the enzyme family Protein Arginine Methyl Transferases. This inhibitor was subsequently characterized further.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2016||Dr. Bokharaei completed his doctoral degree in the field of nanomedicine and drug delivery at the the Faculty of Pharmaceutical Sciences. He designed and optimized a novel system that produces magnetic, protein-based, drug-filled microspheres. These biocompatible particles can be used for the imaging of lung diseases or for liver cancer therapy.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2015||Dr. Mohamed's doctoral studies focussed on development of inhibitors for the Rho-kinase enzyme. This enzyme plays an important role in the development of many diseases. Dr. Mohamed developed novel chemical inhibitors for the enzyme. His findings will aid in the design of new treatments for cardiovascular diseases, cancer and diabetes.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2014||Dr. Wan developed a nanoparticulate drug delivery system. It was demonstrated to be effective in encapsulating high concentration of the aniticancer drugs, paclitaxel and docetaxel, and an inhibitor of the drug efflux protein, P-glycoprotein. His studies suggest a novel way of treating multidrug resistance that is common in many cancer patients.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2014||Dr. Wang examined how the function of an enzyme called lipoprotein lipase is regulated in the heart. She found that this enzyme is controlled by multiple factors, and diabetes disrupts the proper functioning of this enzyme. This research is expected to assist in the development of therapeutic targets that prevent diabetic heart disease.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2014||Dr. Surendradoss investigated the mechanism of drug-induced liver injury. He focussed on the liver injury caused by a commonly used drug called valproic acid, which is used to treat seizures. The findings of his research enabled a greater understanding of the role of various pathways of biotransformation in the liver injury caused by valproic acid||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2013||Dr. Thomas completed his research studying the binding interactions of a family of human enzymes. It was found that the extent of binding controlled how quickly these enzymes could perform their function in the body. This work will allow us to better understand the role of these complexes in the development of cancer and heart disease.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2013||Dr. Erratico investigated a family of enzymes present in the human body, namely the cytochrome P450. He studied their ability to transform two major environmental pollutants. These results show the role that metabolism plays in limiting the ability of these two environmental pollutants to accumulate in the human body.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2013||Dr. Zhang showed that patients who do not use asthma drugs appropriately are more likely to use health services to manage their disease, compared with those who use medications according to guidelines. These findings reinforce to clinicians the importance of closely monitoring patient drug therapy and encouraging appropriate use of asthma drugs.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2013||Dr. War's research focused on breast cancer cells. Using somatostatin receptor-3, which is present on the surface of the cells to receive signals from outside the cells, he developed strategies aimed at treating breast cancer. This work provides valuable information for the better understanding of breast cancer and its treatment.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|